Teva elects David J. Brailer to board, effective Nov. 3

Brailer is expected to serve on Teva’s Human Resources and Compensation and Compliance Committees.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited elected Dr. David J. Brailer to its Board of Directors, effective November 3, 2026, until Teva’s 2027 annual meeting of shareholders. The Board determined that he qualifies as an independent director under New York Stock Exchange listing rules.

Brailer will receive the same compensation as Teva’s other non-executive directors, as described in the company’s March 31, 2026 definitive proxy statement. His roles include Chairman and Chief Executive Officer of medem.ai since 2024, Founder and Executive Chairman of Health Evolution since 2010, and Chief Health Officer of The Cigna Group from 2022 to 2026. Teva stated that no arrangements or understandings led to his election.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Board appointment effective date: November 3, 2026 Board service term: Until the 2027 annual meeting of shareholders Chief Health Officer tenure: 2022–2026

3 metrics

Board appointment effective date November 3, 2026 Effective date of Dr. David J. Brailer’s board service

Board service term Until the 2027 annual meeting of shareholders Term stated for Dr. Brailer’s board service

Chief Health Officer tenure 2022–2026 The Cigna Group

Key Terms

independent director, related party transaction, Israeli Companies Law, 5759-1999

3 terms

independent director regulatory

"qualifies as an independent director under the listing rules"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

related party transaction regulatory

"material interest in any related party transaction"

A related party transaction is any deal or transfer of value between a company and people or entities with close ties to it — such as executives, major owners, family members, or affiliated businesses. Investors watch these transactions because they can favor insiders over outside shareholders, skirt fair market pricing, or hide risks; like selling your car to a relative at a friendly price, they require clear disclosure and scrutiny to judge impact on value.

Israeli Companies Law, 5759-1999 regulatory

"as required pursuant to the Israeli Companies Law, 5759-1999"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does David J. Brailer join the TEVA board?

His board service is effective November 3, 2026, and continues until Teva’s 2027 annual meeting of shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/29/2026 - 05:09 PM EDT Accepted by SEC EDGAR 10/29/2026 - 05:08 PM EDT Learn about SEC filing dates

0000818686false00-000000000008186862026-10-272026-10-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 27, 2026

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

Israel		001-16174		Not Applicable
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

400 Interpace Parkway, #3

Parsippany NJ, 07054 USA

+1-973-658-0301

(Address of principal executive offices, zip code and telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value NIS 0.1 per share		TEVA		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 27, 2026, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva’s 2027 annual meeting of shareholders. The Board determined that Dr. Brailer qualifies as an independent director under the listing rules of the New York Stock Exchange, and he is expected to serve on the Human Resources and Compensation and Compliance Committees of the Board.

Dr. Brailer has served as Chairman and Chief Executive Officer of medem.ai, a health-tech company, since 2024, as Founder and Executive Chairman of Health Evolution since 2010, and as Founder and Managing Partner of Health Evolution Partners since 2007. From 2022 to 2026, Dr. Brailer served as Chief Health Officer of The Cigna Group and, from 2024 to 2026, also as its Chief Transformation Officer. Since 2021, he has served as Vice Chairman of the Duke Margolis Health Policy Institute. Dr. Brailer previously served on the boards of directors of Prolacta Bioscience, Inc. from 2012 to 2023, and Walgreens Boots Alliance, Inc., from 2012 to 2021. Dr. Brailer received a Ph.D. in Management Science and Applied Economics from The Wharton School of the University of Pennsylvania, and an M.D., with honors, and a B.S., cum laude, from West Virginia University. Dr. Brailer has declared in writing that he possesses the requisite skills and expertise, as well as sufficient time, to perform his duties as a director of Teva, as required pursuant to the Israeli Companies Law, 5759-1999.

Dr. Brailer will receive the same compensation as Teva’s other non-executive directors, which is described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 31, 2026.

There are no arrangements or understandings between Dr. Brailer and any other persons pursuant to which Dr. Brailer was elected as a director of the Board. Dr. Brailer does not have a direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Dr. Brailer and any director or executive officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: October 29, 2026	By:	/s/ Eli Kalif
		Name:	Eli Kalif
		Title:	Executive Vice President,
			Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 28.9 KB